Eli Lilly Completes AtaiBeckley Acquisition to Gain Depression Pipeline

Eli Lilly and Company finalized its acquisition of AtaiBeckley Inc. on September 11, 2026. This acquisition expands the pharmaceutical company's neuroscience portfolio with rapid-acting therapies for treatment-resistant depression.

The deal centers on AtaiBeckley’s lead investigational program, BPL-003. This program utilizes neuroplastogens to address depression that has not responded to traditional treatment options. Shareholders of AtaiBeckley approved the transaction at a special meeting before the official closing.

"Treatment-resistant depression persists even after multiple treatment attempts, leaving millions of people still searching for relief," said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience.

Targeting Treatment-Resistant Depression

Treatment-resistant depression is defined clinically as a failure to achieve remission after at least two adequate trials of different antidepressant medications. By incorporating BPL-003, Eli Lilly is entering the field of psychedelic-inspired neuroplastogens. These compounds are hypothesized to promote synaptic plasticity, which is the ability of the brain to form new neural connections.

"AtaiBeckley's neuroplastogens have the potential to open a new paradigm of treatment, with rapid-acting therapeutics designed to move away from chronic dosing," said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience.

Strategic Shift in Neuroscience

This acquisition changes how the industry approaches mental health drug development. Current standards of care for major depressive disorder typically require long-term, daily administration of selective serotonin reuptake inhibitors (SSRIs) or other adjunct medications. The BPL-003 program is intended to provide a therapeutic effect that does not rely on continuous, chronic dosing.

For Eli Lilly, the integration of these assets follows a corporate strategy of diversifying its pipeline beyond its core metabolic and oncology franchises. The company must now navigate the regulatory pathways for these novel neuroplastogens, which remain under clinical investigation. The success of this acquisition depends on the ability of the BPL-003 program to demonstrate safety and efficacy in late-stage clinical trials, as detailed in the official company announcement.